Stepping up inhaler treatment for uncontrolled asthma
Part of Immune system & allergy, Lungs & breathing clinical trials.
This study tests whether switching to a higher-dose or extrafine triple inhaler helps people whose asthma is still uncontrolled on their current medium-dose combination inhaler. It focuses on improving small-airway function, which may lead to better symptom control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and have had asthma for at least 6 months.
- Your asthma must not be well controlled even though you take a medium-dose combination inhaler (ICS/LABA) every day for at least 12 weeks.
- A breathing test (spirometry) must show signs of small-airway disease, with a certain value (FEF25-75%) below 60%.
- You must be able to learn to use a metered-dose inhaler (pMDI) properly, possibly with a spacer.
- You must not have had a severe asthma attack in the last 4 weeks, and you cannot have other lung conditions like COPD or bronchiectasis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares a three-in-one inhaler (ICS/LABA/LAMA) to a two-in-one inhaler (ICS/LABA) for adults whose asthma is not well-controlled despite using a standard two-in-one inhaler. The goal is to see if the triple inhaler improves asthma control better.
This study tests a new three-part asthma inhaler (CHF 5993) in people whose asthma isn't well-controlled even though they're already using two standard asthma medicines together. The goal is to see if adding this new medicine helps control asthma better.
This trial tests whether a new inhaler (CHF5993) works as well as the current standard for adults with mild to moderate asthma. It compares how well the medicine controls asthma and opens airways.
This study tests a new inhaler (PT027) against another inhaler (PT007) for teens aged 12 to 17 with asthma. It looks at how well the new inhaler works when used as needed, and if it is safe.
This Phase 3 trial compares a triple inhaler (FF/UMEC/VI) against the usual double inhaler (FF/VI) to help control asthma symptoms and breathing tests in teens ages 12–17. It also checks how safe and tolerable the treatments are over the study period.
This trial tests whether a new combination inhaler works as well as a commonly used one for teenagers with asthma that is not well controlled. It aims to find a safe and effective treatment option for adolescents.
Hear when a new Asthma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.